Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
8.73
-0.97 (-10.00%)
May 6, 2025, 2:36 PM EDT - Market open
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Stoke Therapeutics stock have an average target of 26, with a low estimate of 17 and a high estimate of 47. The average target predicts an increase of 197.82% from the current stock price of 8.73.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +152.00% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $47 | Strong Buy | Reiterates | $47 | +438.37% | Mar 19, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +174.91% | Mar 19, 2025 |
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +152.00% | Mar 18, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +174.91% | Feb 19, 2025 |
Financial Forecast
Revenue This Year
46.72M
from 36.56M
Increased by 27.80%
Revenue Next Year
51.17M
from 46.72M
Increased by 9.53%
EPS This Year
-1.72
from -1.65
EPS Next Year
-2.37
from -1.72
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 86.1M | 152.3M | 193.2M | ||
| Avg | 46.7M | 51.2M | 68.5M | ||
| Low | 5.9M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 135.5% | 225.9% | 277.6% | ||
| Avg | 27.8% | 9.5% | 33.9% | ||
| Low | -83.9% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.98 | -0.67 | 1.41 | ||
| Avg | -1.72 | -2.37 | -2.07 | ||
| Low | -2.33 | -3.53 | -3.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.